ECSP077169A - Métodos para mejorar la biodisponibilidad de un inhibidor de renina - Google Patents

Métodos para mejorar la biodisponibilidad de un inhibidor de renina

Info

Publication number
ECSP077169A
ECSP077169A EC2007007169A ECSP077169A ECSP077169A EC SP077169 A ECSP077169 A EC SP077169A EC 2007007169 A EC2007007169 A EC 2007007169A EC SP077169 A ECSP077169 A EC SP077169A EC SP077169 A ECSP077169 A EC SP077169A
Authority
EC
Ecuador
Prior art keywords
inhibitor
renina
biodisponibility
improve
methods
Prior art date
Application number
EC2007007169A
Other languages
English (en)
Spanish (es)
Inventor
Gian P Camenisch
Gerhard Gross
Isabel Ottinger
Daniel Wasmuth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077169(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP077169A publication Critical patent/ECSP077169A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EC2007007169A 2004-08-03 2007-01-15 Métodos para mejorar la biodisponibilidad de un inhibidor de renina ECSP077169A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59870004P 2004-08-03 2004-08-03

Publications (1)

Publication Number Publication Date
ECSP077169A true ECSP077169A (es) 2007-02-28

Family

ID=35056890

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007169A ECSP077169A (es) 2004-08-03 2007-01-15 Métodos para mejorar la biodisponibilidad de un inhibidor de renina

Country Status (31)

Country Link
US (1) US7709532B2 (https=)
EP (2) EP1776099B1 (https=)
JP (1) JP5134366B2 (https=)
KR (1) KR20070040384A (https=)
CN (1) CN1993116B (https=)
AR (1) AR050043A1 (https=)
AT (1) ATE449601T1 (https=)
AU (1) AU2005268844B2 (https=)
BR (1) BRPI0514021A (https=)
CA (1) CA2572743C (https=)
CY (1) CY1109826T1 (https=)
DE (1) DE602005017905D1 (https=)
DK (1) DK1776099T3 (https=)
EC (1) ECSP077169A (https=)
ES (1) ES2335597T3 (https=)
HR (1) HRP20100064T1 (https=)
IL (1) IL180678A (https=)
MA (1) MA28821B1 (https=)
MX (1) MX2007001339A (https=)
MY (1) MY142180A (https=)
NO (1) NO20071142L (https=)
NZ (1) NZ552903A (https=)
PE (1) PE20060416A1 (https=)
PL (1) PL1776099T3 (https=)
PT (1) PT1776099E (https=)
RU (1) RU2404758C2 (https=)
SI (1) SI1776099T1 (https=)
TN (1) TNSN07038A1 (https=)
TW (1) TW200616610A (https=)
WO (1) WO2006013094A1 (https=)
ZA (1) ZA200610639B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
EP1927350A1 (en) * 2006-11-24 2008-06-04 Novartis AG Methods for improving bioavailability of a renin inhibitor
CA2769392A1 (en) 2009-07-31 2011-02-03 Sandoz Ag Method for the preparation of w-amino-alkaneamides and w-amino-alkanethioamides as well as intermediates of this method
WO2012010651A2 (en) 2010-07-23 2012-01-26 Sandoz Ag Method for the preparation of omega-amino-alkaneamides and omega-amino-alkanethioamides as well as intermediates of this method
WO2014168255A1 (ja) * 2013-04-12 2014-10-16 国立大学法人京都大学 巨核球の成熟化促進物質
WO2015035218A1 (en) * 2013-09-05 2015-03-12 Howard University Method of increasing the bioavailability of an hiv drug
JP6029621B2 (ja) * 2014-07-14 2016-11-24 ヤマサ醤油株式会社 血漿レニン活性の測定法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108499A (en) 1993-02-04 2000-02-29 Lilly Co Eli Mammalian influx peptide transporter
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
CA2224227A1 (en) 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CN1143680C (zh) * 1997-08-14 2004-03-31 阿旺蒂斯制药公司 增强非索非那定及其衍生物之生物利用度的方法
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
AU3808801A (en) * 2000-02-11 2001-08-20 Praecis Pharmaceuticals Incorporated Methods for enhancing the bioavailability of a drug
WO2001092468A2 (en) * 2000-05-31 2001-12-06 Rutgers, The State University Of New Jersey Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
KR20040066177A (ko) 2001-12-19 2004-07-23 알자 코포레이션 친수성 거대분자의 경구 생체이용률을 증가시키기 위한제형 및 투여 형태
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EP1501546B1 (de) * 2002-05-03 2012-10-10 Hexal AG Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer
PT1517682E (pt) * 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
NZ549535A (en) * 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders

Also Published As

Publication number Publication date
CN1993116B (zh) 2011-04-13
JP2008508340A (ja) 2008-03-21
US20080108703A1 (en) 2008-05-08
MY142180A (en) 2010-10-15
AR050043A1 (es) 2006-09-20
DK1776099T3 (da) 2010-03-01
KR20070040384A (ko) 2007-04-16
ZA200610639B (en) 2008-05-28
PL1776099T3 (pl) 2010-05-31
CN1993116A (zh) 2007-07-04
IL180678A0 (en) 2008-03-20
RU2404758C2 (ru) 2010-11-27
US7709532B2 (en) 2010-05-04
MX2007001339A (es) 2007-03-27
HRP20100064T1 (hr) 2010-03-31
EP1776099B1 (en) 2009-11-25
ATE449601T1 (de) 2009-12-15
DE602005017905D1 (de) 2010-01-07
TNSN07038A1 (en) 2008-06-02
PT1776099E (pt) 2010-01-06
AU2005268844A1 (en) 2006-02-09
CA2572743A1 (en) 2006-02-09
JP5134366B2 (ja) 2013-01-30
IL180678A (en) 2011-04-28
CA2572743C (en) 2012-12-04
WO2006013094A1 (en) 2006-02-09
RU2007107850A (ru) 2008-09-10
EP1776099A1 (en) 2007-04-25
CY1109826T1 (el) 2014-09-10
SI1776099T1 (sl) 2010-03-31
MA28821B1 (fr) 2007-08-01
AU2005268844B2 (en) 2009-03-05
ES2335597T3 (es) 2010-03-30
NZ552903A (en) 2010-09-30
TW200616610A (en) 2006-06-01
EP2191823A1 (en) 2010-06-02
PE20060416A1 (es) 2006-06-09
NO20071142L (no) 2007-04-26
BRPI0514021A (pt) 2008-05-27

Similar Documents

Publication Publication Date Title
ECSP077169A (es) Métodos para mejorar la biodisponibilidad de un inhibidor de renina
EA200800356A1 (ru) Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20051345L (no) Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer
ECSP10010697A (es) Inhibidores de dpp-iv para uso en el tratamiento de nafld
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
EA201101507A1 (ru) Способы лечения солидных опухолей
MX2020008616A (es) Rocio de fentanilo sublingual.
MX2019002774A (es) Inhibidores de la recirculacion de acidos biliares para el tratamiento de hipercolemia y enfermedad hepatica colestasica.
CY1110162T1 (el) Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας
EA200800147A1 (ru) Способ получения олмесартан медоксомила
UY28860A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
CO6382133A2 (es) Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
IL290418A (en) Immune checkpoint inhibitor, therapeutic agent for a disease associated with an immune checkpoint, immunosuppressant, anti-fibronectin antibody or its derivative, fibronectin analog, kit for detecting fibronectin or its partial protein and method for detecting fibronectin or its partial protein
GT200600115A (es) Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
ES2582660T3 (es) Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
MX2009005247A (es) Metodos para mejorar la biodisponibilidad de un inhibidor de renina.